DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance
Article 2024 en
Authors
KC
Kathleen Conway
SE
Sharon N. Edmiston
AV
Amanda M. Vondras
Abstract
1 min read
Melanoma MethylClasses may provide clinical value in predicting 5-year death from melanoma among patients with primary melanoma independent of other clinicopathologic factors.
Grace H. Attrill, Hansol Lee, Annie Tasker, Nurudeen A. Adegoke, Angela L. Ferguson, Inês Pires da Silva, Robyn P.M. Saw, John F. Thompson, Umaimainthan Palendira, Georgina V. Long, Peter M. Ferguson, Richard A Scolyer, James S. Wilmott
Lauren E. Haydu, Serigne Lo, Jennifer L. McQuade, Isabella C. Glitza, Hussein A. Tawbi, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long, Alexander J. Lazar, Michael T. Tetzlaff, Richard A Scolyer, Jeffrey E. Gershenwald, John F. Thompson, Michael A. Davies
Yuan Ni, Caroline G. Watts, Richard A Scolyer, Christine Madronio, Bruce K. Armstrong, Rachael L. Morton, Scott W. Menzies, Graham J. Mann, John F. Thompson, Anne Ε. Cust, Serigne Lo
Urvi Mujumdar, Diana V. Tommasi, Richard A Scolyer, Klaus J. Busam, Bradley J. Bloom, Achim A. Jungbluth, Marianne Berwick, Irene Orlow, Bruce K. Armstrong, Javier Cotignola, John F. Thompson, Colin B. Begg, Irina Ostrovnaya, Nancy E. Thomas
Stefano Rosso, Anne Kricker, Richard A Scolyer, Stephen B. Gruber, Lynn From, Bruce K. Armstrong, Colin B. Begg, Terence Dwyer, Irene Orlow, Peter A. Kanetsky, Rajmohan Murali, Nancy E. Thomas, Klaus J. Busam, Chris Goumas, Marianne Berwick
Discussion(0)
No comments yet. Be the first to comment.